Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. I have no business relationship with any company whose stock is mentioned in this article. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". All Rights Reserved. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . Within eye care, Restasis was a major disappointment, and the entire division seems to be struggling, with total revenues falling from ~$920m in Q2'21, to ~$720m in Q2'22. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. Real-time analyst ratings, insider transactions, earnings data, and more. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. After 2022 Humira's row is shaded yellow to signify patent expiry. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. In-depth profiles and analysis for 20,000 public companies. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. I am not receiving compensation for it (other than from Seeking Alpha). I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Please log in to your account or sign up in order to add this asset to your watchlist. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. To see all exchange delays and terms of use please see Barchart's disclaimer. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. Pharmaceuticals are often valued based on a philosophy of "jam tomorrow" as opposed to jam today i.e. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. That certainly won't derail the oncology division however. Should I buy or sell AbbVie stock right now? It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . Move your mouse over a quarter or year to see how estimates have changed over time. This would represent an increase of 1.78%. Capital Com is an execution-only service provider. Disclaimer. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Finally, AbbVie was able to raise its financial . Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. ABBV currently yields 4.1% and has raised its dividend every year since 2013. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. $163.64. The company provided earnings per share (EPS) guidance of $10.70- for the period. Investors are already flocking there for a chance at 1,000%+ returns. There are currently 9 hold ratings and 7 buy ratings for the stock. The analysts 12-month consensus ABBV stock price target was $159.75. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. If you rely on the information on this page then you do so entirely on your own risk. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. About the AbbVie, Inc. stock forecast. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Their ABBV share price forecasts range from $140.00 to $200.00. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. On average, they expect the company's stock price to reach $161.12 in the next twelve months. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. You should consider whether you understand how CFDs work and can afford the risks. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. Please. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Let's begin our analysis with the immunology division. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. AbbVie Oncology Division Forward Revenue Projections (my table and assumtpions). Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Only 0.08% of the stock of AbbVie is held by insiders. This could present more profit potential for drugmakers as well as investors. It . To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. contact@marketbeat.com A Warner Bros. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. Gene therapies have been a long time coming, having first been popularized in the early noughties. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. You should never invest money you cannot afford to lose. The material provided on this website is for information purposes only and should not be understood as an investment advice. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. During the same quarter in the prior year, the firm posted $3.31 EPS. AbbVie Inc. (NYSE:ABBV) posted its earnings results on Thursday, February, 9th. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. (844) 978-6257. AbbVie passed that onto its 2022 guidance. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. Your current $100 investment may be up to $188.28 in 2028. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. Please. The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. AbbVie is a leader in ESG and sustainability. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. My No. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. The surge in revenues can primarily be attributed to its Allergan. AbbVie projected sales - immunology (my forecasts and assumptions). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Read our dividend analysis for ABBV. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. Skyrizi and Rinvoq will together achieve a higher peak sales figure than even Humira could manage, even while Humira is still making a substantial top line contribution, still accounting for as much of 7% of AbbVie's total sales in 2030. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. It now expects full-year profit in the range of $13.92-$14.12 a share. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. Slide from JPM Conference 2022 presentation. For the next eight years, the forecast is for Free Cash Flow to grow by . What is Richard A. Gonzalez's approval rating as AbbVie's CEO? Neurology also looks strong although aesthetics, eye care and oncology have something to prove. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. View ABBV analyst ratings or view top-rated stocks. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. The median estimate represents a +5.72% increase from the last price of 156.07. AbbVie is a leading dividend payer. On average, analysts rate AbbVie stock as a buy. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. Only you can design whether Abbvie stock is the right investment for you. Wallet Investor suggested that the price could hit $300.386 in June 2027. The Abbvie stock forecast for 2025 had the price at $259.018. Get daily stock ideas from top-performing Wall Street analysts. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. CFDs are complex leveraged instruments and come with a high risk of losing money. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. What other stocks do shareholders of AbbVie own? How often does AbbVie pay dividends? The stock projection varied from the low price target of $135 to the high of $200. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I write about Biotech, Pharma and Healthcare stocks and share investment tips. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. I wrote this article myself, and it expresses my own opinions. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Compare Top Brokerages Here. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. Their ABBV share price forecasts range from $140.00 to $200.00. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. PEG Ratios above 1 indicate that a company could be overvalued. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Identify stocks that meet your criteria using seven unique stock screeners. The ex-dividend date of this dividend is Thursday, April 13th. AbbVie product revenues by quarter and year since FY20. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Myelofibrosis has proved to be a tricky indication for drug developers and there are no wholly satisfactory solutions on the market at present, therefore if approved I would expect Navitoclax - a drug that AbbVie has been working on for some time - to generate a couple of billion dollars in peak sales. And never invest or trade money you cannot afford to lose. This year is off to a strong start. The average price target represents a 6.33% change from the last price of $153.90. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. Trading CFDs is high risk and is not suitable for everyone. Since then, however, the stock price has fallen 18% to. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Zscaler, Inc Plummets, Is It Time To Buy The Dip? I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Receive regular, detailed analysis focused on biotech and healthcare stocks. . This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. What is AbbVie's stock price forecast for 2023? As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. All rights reserved. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. The company issued revenue guidance of -. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Export data to Excel for your own analysis. Kateryna Onyshchuk/iStock via Getty Images. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions). Abbvie stock price has put up an impressive performance in 2022. AbbVie declared a quarterly dividend on Thursday, February 16th. call (03) 8658 0539 support.au@capital.com. 326 E 8th St #105, Sioux Falls, SD 57103 AbbVie has a P/B Ratio of 15.97. (AbbVie JPM Healthcare conference presentation). Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. on the strength of its future rather than present portfolio. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. AbbVie's stock is owned by many different institutional and retail investors. The company is focused on research and has a number of collaborations and partnerships to that end. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026.

Talega Golf Club Membership, Usmc Frog Gear Regulations, Theresa Swann Real Name, Cheryl's Cookies Locations, Articles A